Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation.

Hepatic fibrosis is a common outcome of a variety of chronic liver diseases. Here we evaluated the therapeutic efficacy of hepatocyte growth factor (HGF) on liver fibrosis induced by bile duct ligation (BDL) and investigated potential mechanisms. Mice underwent BDL, followed by intravenous injections of naked HGF expression plasmid or control vector. HGF gene therapy markedly ameliorated hepatic fibrotic lesions, as demonstrated by reduced alpha-smooth muscle actin (alphaSMA) expression, attenuated deposition of type I and type III collagen, and normalized total hydroxyproline content. HGF also suppressed transforming growth factor-beta1 (TGF-beta1) expression. Interestingly, colocalization of alphaSMA and cytokeratin-19 in bile duct epithelium was observed, suggesting the possibility of biliary epithelial to myofibroblast transition after BDL. Cells that were still positive for cytokeratin-19 but actively producing type I collagen were found in the biliary epithelia and periductal region. Laminin staining revealed an impaired basement membrane of the bile duct epithelium in diseased liver. These lesions were largely prevented by HGF administration. In vitro, treatment of human biliary epithelial cells with TGF-beta1 induced alphaSMA and fibronectin expression and suppressed cytokeratin-19. HGF abolished the phenotypic conversion of biliary epithelial cells induced by TGF-beta1. These results suggest that HGF ameliorates hepatic biliary fibrosis in part by blocking bile duct epithelial to mesenchymal transition.

[1]  Youhua Liu.  Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. , 2004, Journal of the American Society of Nephrology : JASN.

[2]  V. Mumaw,et al.  Ductular hepatocytes. Evidence for a bile ductular cell origin in furan-treated rats. , 1994, The American journal of pathology.

[3]  Alain Buisson,et al.  The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling , 2001, Nature Medicine.

[4]  S. Thung,et al.  Identification of bipotential progenitor cells in human liver regeneration. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[5]  K. Matsumoto,et al.  Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. , 2001, Kidney international.

[6]  S. Klahr,et al.  Obstructive nephropathy and renal fibrosis. , 2002, American journal of physiology. Renal physiology.

[7]  S. Vilaró,et al.  Epithelial‐mesenchymal transition of cultured rat neonatal hepatocytes is differentially regulated in response to epidermal growth factor and dimethyl sulfoxide , 1997, Hepatology.

[8]  G. Michalopoulos,et al.  Sustained expression of naked plasmid DNA encoding hepatocyte growth factor in mice promotes liver and overall body growth , 2001, Hepatology.

[9]  S. Friedman,et al.  Fibrogenesis I. New insights into hepatic stellate cell activation: the simple becomes complex. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[10]  D. Brenner,et al.  A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations , 2004, Hepatology.

[11]  M. Zern,et al.  Hepatic stellate cells: a target for the treatment of liver fibrosis , 2000, Journal of Gastroenterology.

[12]  Junwei Yang,et al.  Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. , 2002, Journal of the American Society of Nephrology : JASN.

[13]  S. Forbes,et al.  Hepatic stem cells: from inside and outside the liver? , 2004, Cell proliferation.

[14]  Junwei Yang,et al.  Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. , 2001, The American journal of pathology.

[15]  S. Thorgeirsson,et al.  β-Cell-Specific Ablation of the Hepatocyte Growth Factor Receptor Results in Reduced Islet Size, Impaired Insulin Secretion, and Glucose Intolerance , 2005 .

[16]  G. Michalopoulos,et al.  Liver Regeneration , 1997, Science.

[17]  J. Lunz,et al.  The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. , 2000, The American journal of pathology.

[18]  T. Starzl,et al.  Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. , 2001, The American journal of pathology.

[19]  A. Roberts,et al.  Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. , 2003, The Journal of clinical investigation.

[20]  S. Friedman.  Molecular mechanisms of hepatic fibrosis and principles of therapy , 1997, Journal of Gastroenterology.

[21]  I. Fabregat,et al.  Effects of growth and differentiation factors on the epithelial-mesenchymal transition in cultured neonatal rat hepatocytes. , 1999, Journal of hepatology.

[22]  S. Friedman,et al.  Hepatic fibrosis--role of hepatic stellate cell activation. , 2002, MedGenMed : Medscape general medicine.

[23]  V. Koteliansky,et al.  In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Pinzani,et al.  Liver fibrosis: from the bench to clinical targets. , 2004, Digestive and Liver Disease.

[25]  E. Neilson,et al.  Evidence that fibroblasts derive from epithelium during tissue fibrosis. , 2002, The Journal of clinical investigation.

[26]  Y. Kaneda,et al.  Hepatocyte growth factor gene therapy of liver cirrhosis in rats , 1999, Nature Medicine.

[27]  J. Dranoff,et al.  Secretion of MCP-1/CCL2 by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[28]  D. Roulot,et al.  Transforming growth factor β and the liver , 2001 .

[29]  C. Housset,et al.  Peribiliary myofibroblasts in biliary type liver fibrosis. , 2002, Frontiers in bioscience : a journal and virtual library.

[30]  K. Kivirikko,et al.  Modifications of a specific assay for hydroxyproline in urine. , 1967, Analytical biochemistry.

[31]  Junwei Yang,et al.  Single injection of naked plasmid encoding hepatocyte growth factor prevents cell death and ameliorates acute renal failure in mice. , 2002, Journal of the American Society of Nephrology : JASN.

[32]  Youhua Liu,et al.  Renal fibrosis: new insights into the pathogenesis and therapeutics. , 2006, Kidney international.

[33]  M. Benito,et al.  The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes. , 2002, Molecular cancer research : MCR.

[34]  G. Michalopoulos,et al.  Hepatocytes undergo phenotypic transformation to biliary epithelium in organoid cultures , 2002, Hepatology.

[35]  S. Thorgeirsson,et al.  Overview of recent experimental studies on liver stem cells. , 2003, Seminars in liver disease.

[36]  L. Yang,et al.  Antigenic phenotypes common to rat oval cells, primary hepatocellular carcinomas and developing bile ducts. , 1997, Carcinogenesis.

[37]  G. Michalopoulos,et al.  Transdifferentiation of rat hepatocytes into biliary cells after bile duct ligation and toxic biliary injury , 2005, Hepatology.

[38]  R. Kalluri,et al.  Epithelial-mesenchymal transition and its implications for fibrosis. , 2003, The Journal of clinical investigation.

[39]  Paul Calès,et al.  Fractal dimension can distinguish models and pharmacologic changes in liver fibrosis in rats , 2002, Hepatology.

[40]  S. Friedman,et al.  Hepatic fibrosis. Pathogenesis and principles of therapy , 2001 .

[41]  M. Rastaldi,et al.  Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. , 2002, Kidney international.

[42]  Junwei Yang,et al.  Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. , 2002, Journal of the American Society of Nephrology : JASN.

[43]  Junwei Yang,et al.  Downregulation of Smad transcriptional corepressors SnoN and Ski in the fibrotic kidney: an amplification mechanism for TGF-beta1 signaling. , 2003, Journal of the American Society of Nephrology : JASN.

[44]  A. Eddy.  Molecular basis of renal fibrosis , 2000, Pediatric Nephrology.

[45]  Junwei Yang,et al.  Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. , 2002, The Journal of clinical investigation.

[46]  Youhua Liu.  Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. , 2004, American journal of physiology. Renal physiology.

[47]  S. Thorgeirsson,et al.  Wholesale hepatocytic differentiation in the rat from ductular oval cells, the progeny of biliary stem cells. , 1997, Journal of hepatology.

[48]  K. Matsumoto,et al.  Preventive and therapeutic effects in rats of hepatocyte growth factor infusion on liver fibrosis/cirrhosis , 1997, Hepatology.